Immunome initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Immunome (IMNM) with a Buy rating and $40 price target The company is building a portfolio of “best-in-class, pipeline-in-a-product oncology assets with meaningful differentiation across both validated and underpenetrated solid tumor and hematologic indications,” the analyst tells investors in a research note. H.C. Wainwright sees Immunome’s portfolio as a “coordinated set of value drivers.”